Quick Answer
Organogenesis Holdings Inc. reported Research And Development Expense of $44.54 million for the year ending 2025.
- Organogenesis Holdings Inc. showed a decrease of -11.4% in Research And Development Expense from 2024 to 2025.
- This data is from Organogenesis Holdings Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $1.55 million | Q2 2017: $2.45 million | Q3 2017: $2.33 million | Q4 2017: $2.74 million | Q1 2018: $2.82 million | Q2 2018: $2.05 million | Q3 2018: $2.78 million | Q4 2018: $3.09 million | Q1 2019: $3.37 million | Q2 2019: $3.86 million | Q3 2019: $3.92 million | Q1 2020: $5.41 million | Q2 2020: $4.67 million | Q3 2020: $3.71 million | Q1 2021: $6.21 million | Q2 2021: $7.32 million | Q3 2021: $8.95 million | Q1 2022: $8.59 million | Q2 2022: $10.21 million | Q3 2022: $9.58 million | Q1 2023: $11.20 million | Q2 2023: $10.94 million | Q3 2023: $10.47 million | Q1 2024: $12.81 million | Q2 2024: $15.59 million | Q3 2024: $10.34 million | Q1 2025: $10.64 million | Q2 2025: $10.40 million | Q3 2025: $13.22 million.
- Over the full 10 years of available data (2016 to 2025), Organogenesis Holdings Inc.'s Research And Development Expense has grown by 609.6%.
- Historical annual values: Fiscal year 2025: $44.54 million | Fiscal year 2024: $50.27 million | Fiscal year 2023: $44.38 million | Fiscal year 2022: $39.76 million | Fiscal year 2021: $30.74 million | Fiscal year 2020: $20.09 million | Fiscal year 2019: $14.80 million | Fiscal year 2018: $10.74 million | Fiscal year 2017: $9.07 million | Fiscal year 2016: $6.28 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: